Eledon Pharmaceuticals, Inc. (ELDN) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$22.87M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$21.18M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$19.07M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$24.73M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$22.87M | (m) | (m) | (m) | (m) | -$22.68M* | (m) | $18.23M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$21.18M | (m) | (m) | (m) | (m) | -$22.61M | (m) | $17.20M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$19.07M | (m) | (m) | (m) | (m) | -$14.48M* | (m) | $14.97M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$24.73M | (m) | (m) | (m) | (m) | -$17.71M* | (m) | $20.28M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$17.96M | (m) | (m) | (m) | (m) | -$16.06M | (m) | $13.53M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$20.51M | (m) | (m) | (m) | (m) | -$11.77M* | (m) | $16.52M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$14.50M | (m) | (m) | (m) | (m) | -$7.77M* | (m) | $10.11M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$10.87M | (m) | (m) | (m) | (m) | -$8.74M | (m) | $7.41M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$11.20M | (m) | (m) | (m) | (m) | -$12.25M* | (m) | $7.93M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$10.35M | (m) | (m) | (m) | (m) | -$8.22M* | (m) | $7.20M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$11.11M | (m) | (m) | (m) | (m) | -$9.92M | (m) | $8.11M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$10.60M | (m) | (m) | (m) | (m) | -$4.57M* | (m) | $7.45M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$9.28M | (m) | (m) | (m) | (m) | -$6.22M* | (m) | $5.74M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$9.86M | (m) | (m) | (m) | (m) | -$8.16M | (m) | $6.63M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$10.51M | (m) | (m) | (m) | (m) | -$7.09M* | (m) | $7.66M | (m) | -$686.00K |
| 2021-06-30 | Reported | (m) | -$7.97M | (m) | (m) | (m) | (m) | -$7.45M* | (m) | $4.24M | (m) | -$588.00K |
| 2021-03-31 | Reported | (m) | -$9.01M | (m) | (m) | (m) | (m) | -$5.17M | (m) | $5.65M | (m) | -$501.00K |
| 2020-09-30 | Reported | (m) | -$6.15M | (m) | (m) | (m) | (m) | -$561.00K* | (m) | $615.00K | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$2.59M | (m) | (m) | (m) | (m) | -$3.02M* | (m) | $832.00K | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$3.38M | (m) | (m) | (m) | (m) | -$2.20M | (m) | $1.65M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$2.92M | (m) | (m) | (m) | (m) | -$2.89M* | (m) | $1.51M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$4.09M | (m) | (m) | (m) | (m) | -$4.92M* | (m) | $2.30M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$4.88M | (m) | (m) | (m) | (m) | -$4.02M | (m) | $2.99M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$3.50M | (m) | (m) | (m) | (m) | -$2.94M* | (m) | $1.65M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$3.19M | (m) | (m) | (m) | (m) | -$3.33M* | (m) | $1.33M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$2.79M | (m) | (m) | (m) | (m) | -$2.27M | (m) | $1.10M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$2.96M | (m) | (m) | (m) | (m) | -$3.42M* | (m) | $517.00K | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$6.67M | (m) | (m) | (m) | (m) | (m) | (m) | $533.00K | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$1.39M | (m) | (m) | (m) | (m) | (m) | (m) | $479.00K | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$3.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$1.62M | (m) | (m) | (m) | $2.00K* | (m) | (m) | $1.05M | (m) | $0.00* |
| 2016-06-30 | Reported | (m) | -$932.00K | (m) | (m) | (m) | -$7.00K* | (m) | (m) | $592.00K | (m) | $0.00* |
| 2016-03-31 | Reported | (m) | -$11.48M | (m) | (m) | (m) | $17.00K | (m) | (m) | $7.93M | (m) | $0.00 |
| 2015-12-31 | Reported | (m) | -$11.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$11.91M | (m) | (m) | (m) | $157.00K* | (m) | (m) | $8.49M | (m) | $0.00* |
| 2015-06-30 | Reported | (m) | -$8.98M | (m) | (m) | (m) | $147.00K* | (m) | (m) | $5.86M | (m) | $0.00* |
| 2015-03-31 | Reported | (m) | -$13.30M | (m) | (m) | (m) | $45.00K | (m) | (m) | $10.56M | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$6.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$6.42M | (m) | (m) | (m) | $7.00K* | (m) | (m) | $2.83M | (m) | $0.00* |
| 2014-06-30 | Reported | (m) | -$5.88M | (m) | (m) | (m) | $6.00K* | (m) | (m) | $4.39M | (m) | $0.00* |
| 2014-03-31 | Reported | (m) | -$4.89M | (m) | (m) | (m) | $12.00K | (m) | (m) | $3.56M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$5.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$3.37M | (m) | (m) | (m) | (m) | (m) | (m) | $2.70M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$4.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$2.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | Reported | (m) | -$43.00M | (m) | (m) | (m) | (m) | -$39.53M | (m) | $30.31M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$88.43M | (m) | (m) | (m) | (m) | -$28.42M | (m) | $27.08M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$36.87M | (m) | (m) | (m) | (m) | -$28.91M | (m) | $23.73M | (m) | -$2.35M |
| 2020-12-31 | Reported | (m) | -$18.46M | (m) | (m) | (m) | (m) | -$15.21M | (m) | $6.13M | (m) | -$404.00K |
| 2019-12-31 | Reported | (m) | -$16.05M | (m) | (m) | (m) | (m) | -$13.86M | (m) | $8.13M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$14.06M | (m) | (m) | (m) | (m) | -$11.89M | (m) | $6.82M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$13.12M | (m) | (m) | (m) | (m) | -$14.94M | (m) | $2.02M | (m) | (m) |
| 2017-09-30 | Rolling | (m) | -$14.78M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | -$13.43M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | -$7.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$5.13M | (m) | (m) | (m) | $9.00K | (m) | (m) | $3.19M | (m) | $0.00 |
| 2016-12-31 | Rolling | (m) | -$17.79M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$25.10M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$35.39M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$43.44M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$45.26M | (m) | (m) | (m) | $565.00K | (m) | (m) | $32.64M | (m) | $0.00 |
| 2015-12-31 | Rolling | (m) | -$45.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Rolling | (m) | -$40.45M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | Rolling | (m) | -$34.97M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | Rolling | (m) | -$31.87M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$23.46M | (m) | (m) | (m) | $25.00K | (m) | (m) | $14.58M | (m) | $0.00 |
| 2014-12-31 | Rolling | (m) | -$23.46M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Rolling | (m) | -$22.75M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | Rolling | (m) | -$19.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | Rolling | (m) | -$18.25M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$15.75M | (m) | (m) | (m) | $23.00K | (m) | (m) | $12.20M | (m) | $0.00 |
| 2013-12-31 | Rolling | (m) | -$15.75M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$9.65M | (m) | (m) | (m) | $8.00K | (m) | (m) | $7.37M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |